Previsión
| Comprar |
5 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Lineage Cell Therapeutics advances preclinical pipeline and extends cash runway to Q3 2028
Lineage reported preclinical progress in corneal disease, Type 1 diabetes and hearing-loss programs while Roche and Genentech continue optimizing surgical delivery for lead OpRegen. The OPC1 DOSED study has treated two chronic spinal-cord-injury patients with no unexpected safety issues, though it is not designed to assess efficacy. Lineage highlighted its AlloSCOPE manufacturing platform aimed at scalable allogeneic production and said existing GMP banks have been FDA-cleared and used in OpRegen trials. The company ended Q2 with $50.8 million in cash and marketable securities, extending its expected runway into Q3 2028, and remains eligible for up to $615 million in milestones plus tiered royalties from the Roche/Genentech deal. » Más en finance.yahoo.com
Lineage Cell Therapeutics reports Q2 profit and extends financing through Q3 2028
Lineage Cell Therapeutics reported a net profit of $1.5 million in the second quarter of 2026 on revenue that fell to $1.1 million. Cash and marketable securities amounted to $50.8 million as of June 30, which the company says finances operations through the third quarter of 2028. The reported gain was largely non‑cash, stemming from a revaluation of option-related liabilities, while operating activities still showed a loss of $8.9 million. Management emphasizes the “Lineage 3.0” platform strategy and points to ongoing partnerships such as OpRegen with Roche/Genentech, as well as expected pipeline updates before the end of 2026. » Más en de.investing.com
Lineage Cell Therapeutics files prospectus supplement for stock offering of up to $60 million
Lineage Cell Therapeutics has filed a prospectus supplement with the SEC for the potential sale of common stock totaling up to $60 million. The shares would be offered from time to time under an existing distribution agreement with B. Riley Securities; the supplement is part of an existing shelf registration (Form S-3). The company emphasized that the notice does not constitute an offer to sell and attached a legal opinion; it also highlighted progress in the OpRegen program with Roche/Genentech and received a buy recommendation from H.C. Wainwright with a $9.00 price target. » Más en de.investing.com
Lineage Cell Therapeutics withdraws CIRM grant application and plans resubmission
Lineage Cell Therapeutics withdrew its CLIN2 grant application to the California Institute for Regenerative Medicine after receiving feedback and plans to submit a revised application in the next CIRM cycle in January 2026. CIRM did not identify any specific substantive deficiencies, and the company will continue development activities for OPC1 unchanged. The ongoing DOSED study for OPC1 administration is proceeding as planned. Lineage also reported Q3 results with EPS of -$0.13 (below expectations) and revenue of $3.68 million (above expectations), raised $21 million through an ATM sale, and reported its stock price and market capitalization. » Más en de.investing.com
Lineage reaches 52-week low at $32.78
Lineage stock fell to a 52-week low of $32.78 and is currently trading near that level, well below its high of $66.38. Year-to-date the price is down about 41.04%, and it fell 48.21% last year. InvestingPro rates the stock as fairly valued, with analyst price targets ranging from $38 to $70. For Q3 Lineage reported record revenue of $1.37 billion but posted a loss per share and cut its full-year forecast; several banks have lowered price targets or adjusted ratings. Despite the loss, Lineage offers a dividend yield of 6.32%, providing investors with short-term income at increased risk. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2003, Lineage Cell Therapeutics ya ha pagado 0,0651 € en dividendos. El último pago fue en diciembre de 2003.
Datos financieros
En el último trimestre, Lineage Cell Therapeutics tuvo unos ingresos de 1,27 M € y un beneficio neto de 3,74 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 1,27 M | 59,64 % |
| Beneficio bruto | 1,26 M | 59,72 % |
| Beneficio neto | 3,74 M | 114,72 % |
| EBITDA | 4,34 M | 117,22 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 177,95 M € |
Número de acciones | 252,95 M |
Máximo/mínimo de 52 semanas | 1,81 € - 0,70 € |
| Dividendos | No |
Beta | 1,69 |
Ratio P/E | -25,56 |
Ratio PEG | -0,15 |
Ratio P/B | 2,91 |
Ratio P/S | 18,02 |
Perfil de la empresa
Lineage Cell Therapeutics, Inc., una empresa de biotecnología en fase clínica, desarrolla terapias celulares novedosas para el tratamiento de enfermedades degenerativas en Estados Unidos y a nivel internacional. La compañía desarrolla OpRegen, una terapia de reemplazo de células del epitelio pigmentario retiniano, que se encuentra en un ensayo clínico de Fase I/IIa para el tratamiento de la degeneración macular seca relacionada con la edad; OPC1, una terapia con células progenitoras de oligodendrocitos que se encuentra en un ensayo clínico multicéntrico de Fase I/IIa para el tratamiento de lesiones agudas de la médula espinal; y VAC2, una inmunoterapia alogénica contra el cáncer basada en células dendríticas presentadoras de antígenos, que se encuentra en un ensayo clínico de Fase I para tratar el cáncer de pulmón de células no pequeñas. También ofrece Renevia, un producto de estética facial. Además, la empresa se dedica a la investigación y desarrollo de productos terapéuticos para enfermedades retinianas, enfermedades neurológicas, trastornos y oncología. Lineage Cell Therapeutics, Inc. mantiene una colaboración con Orbit Biomedical, Ltd. La compañía era anteriormente conocida como BioTime, Inc. y cambió su nombre a Lineage Cell Therapeutics, Inc. en agosto de 2019. Lineage Cell Therapeutics, Inc. fue constituida en 1990 y tiene su sede en Carlsbad, California.
| Nombre | Lineage Cell Therapeutics |
| CEO | Brian Culley |
| Sede | Carlsbad,
ca Estados Unidos |
| Sitio web | |
| Sector | Consumo básico |
| Industria | Productos alimenticios |
| Salida a bolsa | 05/03/1992 |
| Empleados | 75 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Tlv | LCTX.TA |
AMEX | LCTX |
Frankfurt | BT3.F |
Düsseldorf | BT3.DU |